To confirm our results, we tested a second inhibitor of PP2A, LB-100, a recently developed molecule that is being studied in cancer clinical trials [12, 32], and which is part of a family of compounds with stronger specificity for PP2A compared to PP1 (IC50 PP2A = 0.4 μM, IC50 PP1 = 80 μM) [39]. Here, PTPA is linked to cancer.